Relmada Therapeutics Inc RLMD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RLMD is a good fit for your portfolio.
News
-
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
-
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024
-
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Trading Information
- Previous Close Price
- $3.86
- Day Range
- $3.66–3.81
- 52-Week Range
- $2.36–7.22
- Bid/Ask
- $3.70 / $4.01
- Market Cap
- $111.64 Mil
- Volume/Avg
- 85,873 / 217,373
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 20
- Website
- https://www.relmada.com
Comparables
Valuation
|
Metric
|
RLMD
|
CBAY
|
PLRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.36 | 12.65 | 1.51 |
Price/Sales | — | 111.01 | 442.25 |
Price/Cash Flow | — | — | — |
Price/Earnings
RLMD
CBAY
PLRX
Financial Strength
|
Metric
|
RLMD
|
CBAY
|
PLRX
|
|---|---|---|---|
Quick Ratio | 7.90 | 10.70 | 17.43 |
Current Ratio | 8.00 | 10.96 | 17.72 |
Interest Coverage | — | −5.27 | −145.34 |
Quick Ratio
RLMD
CBAY
PLRX
Profitability
|
Metric
|
RLMD
|
CBAY
|
PLRX
|
|---|---|---|---|
Return on Assets (Normalized) | −44.34% | −30.06% | −22.68% |
Return on Equity (Normalized) | −48.59% | −51.97% | −24.50% |
Return on Invested Capital (Normalized) | −53.16% | −30.87% | −28.46% |
Return on Assets
RLMD
CBAY
PLRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Grddkntx | Qymz | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tkfnhdmfx | Btpksw | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rfbmzmn | Wlwwkd | $99.5 Bil | |
MRNA
| Moderna Inc | Gkhxfhwf | Kqnx | $38.8 Bil | |
ARGX
| argenx SE ADR | Mgnzrbjs | Npn | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Lbprhcy | Nlnm | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fjhtlmhv | Yvwnb | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nwktjtz | Vmtnm | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nqhybmrm | Slbsns | $12.5 Bil | |
INCY
| Incyte Corp | Bqkgpdb | Rjqspb | $11.6 Bil |